Vaccine News and Research

Latest Vaccine News and Research

Shingles vaccine reduces risk of herpes zoster disease in older patients

Older adults who get the shingles vaccine have a nearly 50 percent reduced risk of developing the often debilitating disease, finds a new evidence review from The Cochrane Library.

20 Oct 2012

New data shows influenza-associated deaths among children, effectiveness of school vaccinations

New data being presented at IDWeek 2012TM shows the fatal risk that influenza poses even for children without underlying health conditions and the effectiveness of school-based vaccination programs in protecting student populations.

20 Oct 2012

Sanofi Pasteur files Fluzone sBLA with FDA for treatment of influenza

Sanofi Pasteur, the vaccines division of Sanofi, announced today that it has filed a Supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) for a quadrivalent formulation of its Fluzone (Influenza Virus Vaccine).

20 Oct 2012

Babies born to HIV positive mothers more likely to acquire measles

Non-infected babies born to HIV positive mothers should be vaccinated early against measles, to avoid them acquiring the virus or passing it on to others.

19 Oct 2012

Link between norovirus outbreaks and excess hospitalization and mortality in nursing homes

In a study that included more than 300 Medicare-certified nursing homes, rates of hospitalization and death were substantially increased during outbreaks of norovirus gastroenteritis vs. non-outbreak periods, according to a study appearing in the October 24/31 issue of JAMA.

19 Oct 2012

Lupus investigators receive LRI's first $1 million research grants

The Lupus Research Institute (LRI) today announced the first $1 million research grants given to lupus investigators by a private research organization.

19 Oct 2012

Political will, humanitarian effort, funding all needed to eradicate polio

Though "conflict and insecurity problems in Afghanistan, Pakistan, and Nigeria have presented challenges to polio immunization, ... these are surmountable obstacles," Siddharth Chatterjee, chief diplomat and head of strategic partnerships and international relations at the International Federation of the Red Cross and Red Crescent Societies, writes in the International Peace Institute's Global Observatory.

19 Oct 2012

Global anti-tuberculosis campaign now ‘at a crossroads’

Tuberculosis care and control has improved dramatically over the last two decades, but numbers of cases and deaths are still high and multidrug resistant-TB is an under-reported and ever-increasing problem, suggest findings from the World Health Organization Global TB Report 2012.

18 Oct 2012

Trial results of first new TB vaccine candidate in 90 years expected next year

"Researchers will find out early next year whether the first new vaccine against tuberculosis [TB] for 90 years protects against a disease that was once neglected but is now resurgent worldwide," Financial Times reports.

18 Oct 2012

NPR examines efforts to eradicate polio in Nigeria

NPR's "Shots" blog reports on efforts to eradicate polio in Nigeria. "[N]orthern Nigeria is the only place in the world where polio cases are increasing," the blog writes, noting, "As of Sept. 1, it had recorded 90 polio cases in 2012 -- or nearly three times as many as in the same period last year."

18 Oct 2012

NPR begins series on polio eradication

NPR's "Shots" blog on Monday began a series of stories "reporting on the fight to eradicate the last few pockets of polio," which begins "with a look back at how the U.S. and the rest of the world wiped out the virus for good."

17 Oct 2012

Public-private partnership will promote handwashing to help reduce child mortality in Africa

Though the number of children dying of preventable and treatable diseases worldwide has dropped significantly since 1990, there is "realistic hope for much more" progress, particularly if "improved hygiene and sanitation ... play a key role in the next stage," Jeffrey Sachs, director of the Earth Institute at Columbia University, and Paul Polman, CEO of Unilever, write in the Huffington Post's "Global Motherhood" blog.

17 Oct 2012

NIAID-funded study to evaluate PPSV23 and PCV13 in Phase Iib pneumococcal trial

Researchers plan to see if a higher dose of a pneumococcal vaccine will create a stronger immune response in older adults who received an earlier generation vaccine against pneumonia and other pneumococcal diseases.

16 Oct 2012

Current status, challenges and opportunities of pulmonary vaccine delivery

In addition to the obvious benefit of eliminating the need for an injection, new vaccine delivery methods via the lungs offer particular advantages for protecting against infectious agents that enter the body through the respiratory track.

16 Oct 2012

GAPPS announces five new projects for prevention of preterm births

Five innovative research projects aiming to prevent premature birth were announced today by the Global Alliance to Prevent Prematurity and Stillbirth (GAPPS), an initiative of Seattle Children's.

16 Oct 2012

Saint Louis University to participate in PPV23 vaccine trial for pneumonia

Saint Louis University is participating in a multi-site, National Institutes of Health-sponsored clinical trial in older adults of a new vaccine designed to protect against one of the most common types of pneumonia and related diseases such as bloodstream infections and meningitis.

16 Oct 2012

Taking technology from the lab to the patient: SMART Arm™: Hand of hope for stroke survivors

Creating a viable commercial product from its beginnings as a research concept through to a final product patients can use is a long, difficult and often expensive process. However, as David Henderson, the Managing Director of UniQuest, one of the leading technology transfer companies in the Asia Pacific region explains, a focus on patient needs is vital for developing a successful product.

15 Oct 2012

Therapeutic HPV16 and HPV18 vaccine ‘may eliminate infection’

A candidate vaccine against human papillomavirus serotypes 16 and 18 appears to induce robust immune responses to antigens, potentially leading to the elimination of virus-infected cells and regression of dysplasia, say US investigators.

15 Oct 2012

Enrollment complete in Idera's IMO-3100 Phase 2 trial for psoriasis

Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.

15 Oct 2012

Researchers identify keys and doors of Anaplasmataceae tick-borne bacterium

Virginia Commonwealth University School of Medicine researchers have identified the "keys" and "doors" of a bacterium responsible for a series of tick-transmitted diseases. These findings may point researchers toward the development of a single vaccine that protects against members of an entire family of bacteria that cause disease in humans, domestic animals and livestock.

15 Oct 2012